Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on May 13, 2025, regarding events occurring on May 8, 2025. The filing details the entry into a new material definitive loan agreement and a concurrent private placement of equity securities.
Key Financial Metrics and Capital Structure
- New Debt Facility: Entered into a Loan Agreement with Blackstone for an aggregate principal amount of up to $570.0 million.
- Initial Funding: $120.0 million in a first lien senior secured term loan funded on the Closing Date.
- Available Capacity: $180.0 million in additional term loans (split into two tranches available until May 2026 and May 2027) and a $70.0 million super senior revolving credit facility.
- Incremental Capacity: Option to request up to $200.0 million in incremental term loans subject to lender consent.
- Interest Rates: Term Loans bear interest at Term SOFR + 4.75%; Revolver bears interest at SOFR + 4.00%. A 2.00% penalty applies during an Event of Default.
- Maturity: All loans mature five years from the Closing Date (May 8, 2030).
- Equity Raise: Private placement of 140,000 shares of common stock at $107.14 per share, generating gross proceeds of approximately $15.0 million.
- Liquidity Covenant: Minimum liquidity requirement of $30 million, tested quarterly.
Material Changes Versus Prior Period
- Debt Refinancing: Proceeds from the new Term Loans, combined with cash on hand, were used to repay in full the Company's existing term loan under its Credit Agreement with Hercules Capital, Inc.
- Termination: The Existing Hercules Credit Agreement was terminated in connection with the payoff.
- Capitalization: Issuance of unregistered equity securities pursuant to Section 4(a)(2) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
- Security Interest: Obligations are secured by a first lien security interest in certain assets of the Company and its Guarantors.
- Prepayment Provisions: Mandatory prepayment may be required upon a change of control, incurrence of certain additional indebtedness, asset sales, or an event of loss. Voluntary prepayment of Term Loans is subject to yield protection premiums.
- Lock-Up Period: Purchasers in the Private Placement are subject to a 120-day lock-up period prohibiting the sale or transfer of securities.
- Default Consequences: In the event of a continuing default, lenders may declare all amounts outstanding immediately due and payable.
Key Facts for Investor Verification
- Verify the exact amount of cash on hand used alongside the $120.0 million loan to fully repay the Hercules Capital debt.
- Confirm the specific assets pledged as collateral under the first lien security interest.
- Review the full text of the Loan Agreement (to be filed in the next periodic report) for detailed affirmative and negative covenants.
- Monitor the Company's quarterly liquidity position to ensure compliance with the $30 million minimum liquidity covenant.
- Assess the impact of the 4.75% margin on Term SOFR on future interest expense relative to the previous Hercules agreement.